Browse pathology - cardiology database

agents to slow down human AAA-expansion

all type of patients   

endovascular treatment

all type of patients   

patient with large AAA   

patients with small AAA   

anti-anginal drugs

all type of patients   

anticoagulant

All ACS (including AMI)   

ACS (excluding AMI)   

antiplatelets drug

ACS (excluding AMI)   

patients with scheduled percutaneous coronary intervention   

all type of patients   

STEMI patients   

antithrombotics

all type of patient   

unstable angina   

patients managed with an early invasive strategy   

PCI sub group   

patients with a recent ACS   

calcium channel blockers

all type of patients   

cholesterol lowering intervention

early initiation   

direct factor Xa inhibitors

all type of patients   

direct oral anticoagulant (DAO)

all type of patients   

fibrinolysis

all type of patients   

heparin (UFH or LMWH)

all type of patients   

myocardial revascularization

all type of patients   

Elderly patients   

New P2Y12 Inhibitors

all type of patients   

nitrates

all type of patients   

oxygen therapy

all type of patients   

angiotensin-Converting Enzyme Inhibitors

systematic early treatment (with or without sign of HF)   

patients with or without HF   

patients with left ventricular dysfunction after MI   

angiotensin-receptor blockers

all type of patients   

antiarrythmic drugs

all type of patients   

anticoagulant

all type of patients   

antiplatelets drug

all type of patients   

antithrombotics

all type of patients   

beta-blockers

immediate beta-blockers   

long term beta-blockers   

calcium channel blockers

acute short term and post MI studies   

acute (short term) treatment   

long term studies   

cell-based therapies

PCI   

cholesterol lowering intervention

all type of patients   

complement inhibition

all type of patients   

patient undergoing primary angioplasty   

fibrinolysis

all type of patients   

>6h from onset of symptoms   

glucose insulin potassium

all type of patients   

heparin (UFH or LMWH)

patients eligible to receive fibrinolytic therapy   

ICD

all type of patients   

increasing hemoglobin concentration

patients undergoing PCI   

Late revascularisation

late reperfusion   

myocardial revascularization

facilated PCI   

all type of patients   

failed fibrinolysis (rescue revascularisation)   

patients in cardiogenic shock   

>6h from onset of symptoms   

patient ineligible for thrombolysis   

patients with inducible post MI ischemia   

Elderly patients   

new drug under development

nitrates

all type of patients   

oxygen therapy

all type of patients   

PCI

all type of patients   

patient ineligible for thrombolysis   

patients with inducible post MI ischemia   

failed fibrinolysis (rescue PCI)   

Elderly patients   

percutaneous left ventricular assist device

patients with cardiogenic shock   

percutaneous left ventricular assist devices

cardiogenic shock   

thrombectomy

all type of patients   

cholesterol lowering intervention

all type of patients   

transcatheter aortic-valve implantation (TAVI)

all type of patients   

antiarrythmic drugs

maintaining sinus rhythm after cardioversion   

rate control   

prevention of cardiovascular events   

antithrombotics

primary prevention of thromboembolic events   

secondary prevention of thromboembolic events   

patients ineligible for warfarin   

catheter ablation

all type of patients   

direct antithrombins

all type of patients   

direct factor Xa inhibitors

all type of patients   

direct oral anticoagulant (DAO)

all type of patients   

embolic protection

all type of patients   

prevention

patient with history of atrial fibrillation   

patients without history of AF (primary prevention)   

rate control

all type of patients   

rythm control

all type of patients   

pacemaker

all type of patients   

antiplatelets drug

all type of patients   

cholesterol lowering intervention

preoperative statins   

off-pump CABG

all type of patients   

preconditioning

all type of patients   

radial graft

all type of patients   

vein grafts pretreatment

all type of patients   

active compression-decompression CPR

all type of patients   

antiarrythmic drugs

out hospital patients   

compression-only CPR

all type of patients   

fibrinolysis

all type of patients   

modified resuscitation protocol

all type of patients   

omega-3 fatty acids

patients with an implantable cardioverter defibrillator   

Public Access Defibrillation

all type of patients   

vasopressin

all type of patients   

ACAT inhibition

all type of patients   

anticoagulant

antioxydants

all type of patients   

diabetic patients   

patients with renal disease   

primary prevention   

secondary prevention   

antiplatelets drug

diabetic patients   

all type of patients   

secondary prevention in patients with intermittent claudication   

secondary prevention in patients with CAD   

primary prevention   

patients without established disease   

antithrombotics

patienst at high risk   

all type of patients   

primary prevention   

CEPT inhibition

all type of patients   

cholesterol lowering intervention

patients with LDL elevation and without CHD   

diabetic patients   

elderly   

high risk patients with or without LDL cholesterol elevation   

patients with prior MI or with CHD   

patients with other atherosclerotic localisation   

patient with related disease   

all chronical situations   

post stroke (or TIA)   

primary prevention   

patients with renal insufficiency (on hemodialysis or transplant)   

women   

diet

all type of patients   

dietary salt reduction

all type of patients   

HDL increasing drugs

all type of patients   

hormonal replacement therapy

all type of patients   

primary prevention   

secondary prevention   

lifestyle intervention

all type of patients   

primary prevention   

niacin

all type of patients   

omega-3 fatty acids

all type of patients   

patients at high risk   

pateints at low risk   

PCSK9 Inhibitors

all type of patients   

plasma homocysteine lowering intervention

all type of patients   

polypill

all type of patients   

weight-loss drugs

overweight or obese patients   

diabetic patients   

endarterectomy

asymptomatic patients   

symptomatic patients   

endovascular treatment

all type of stenosis   

anti-anginal drugs

all type of patients   

hemodialysis patients   

cell-based therapies

untractable angina   

all type of patients   

death and events prevention

all type of patients   

Drug eluting stent

all type of patients   

diabetic patients   

acute myocardial infarction   

long or complex lesion   

bypass graft lesion   

in stent restenosis   

unprotected left main artery stenosis   

bifurcation lesion   

unparticular patients   

total occlusion   

small vessels   

fractional-flow-reserve-guided PCI

all type of patients   

myocardial revascularization

all type of patient   

diabetic patients   

multivessels disease   

single vessel disease   

patients with left ventricular dysfunction   

transmyocardial revacularization

all type of patients   

alpha-glucosidase inhibitors

all type of patients   

angiotensin renin system blockade

all type of patients   

angiotensin-receptor blockers

all type of patients   

anti hypertensive agent

type1 and 2 diabetic patients with hypertension   

patients with or without hypertension   

antidiabetic drugs

all types of patients   

patients inadequately controlled on metformin   

Patients inadequately controlled on MET+SU therapy   

patients with insufficient glycaemic control with bitherapy   

patients inadequately controlled on monotherapy   

patients inadequately controlled with insulin   

in patients inadequately controlled on standard therapy   

patients inadequately controlled on TZD   

drug naïve patients   

patients insufficiently controlled on SU   

antidiabetic drugs added to metformin

antioxydants

all type of patients   

antiplatelets drug

patients without cardiovascular disease   

all type of patients   

antithrombotics

cholesterol lowering intervention

diabetic patients with or withour hypercholesterolemia   

glucose lowering for cardiovascular prevention

all type of patients   

insulin secretagogues

all type of patients   

insulin secretagogues - DPP-4 inhibitors

all types of patients   

insulin secretagogues - Meglitinides (glinides)

all types of patients   

insulin secretagogues - sulfonylureas

all type of patients   

insulin secretagogues peptides (incretins)

all type of patients   

insulin sensitizer

all type of patients   

patients with cardiovascular disease   

insulin sensitizer - biguanides

all type of patients   

insulin sensitizers - glitazones

all type of patients   

patients with cardiovascular disease   

insulin sensitizers - PPAR modulator

all types of patients   

insulin therapy

all type of patients   

intensive glycemic control

Type 1 and 2 diabetes   

type 2 diabetes (NIDD)   

intensive therapy

all type of patients   

prevention

all type of patients   

people with impaired glucose tolerance   

screening for CAD

all type of patients   

SGLT2 inhibitors

all type of patients   

weight-loss drugs

all type of diabetics   

anticoagulant

orthopedic surgery   

antiplatelets drug

orthopedic surgery   

general surgery   

all type of patients   

medical patients   

elective orthopedic surgery   

antithrombotics

orthopedic surgery   

elective major knee surgery   

elective hip replacement   

hip Fracture   

medical patients   

general surgery   

urologic surgery   

gynaecological surgery   

abdominal surgery   

neurosurgery   

arthroscopy   

patients with immobilization of the lower extremities   

patients with myocardial infarction   

direct antithrombins

orthopedic surgery   

all type of patients   

direct factor Xa inhibitors

all type of patients   

direct oral anticoagulant (DAO)

all type of patients   

elective major knee surgery   

elective hip replacement   

orthopaedic surgery   

medical patients   

graduated compression stockings

all type of patients   

heparin (UFH or LMWH)

orthopedic surgery   

general surgery   

neurosurgery   

LMWH

orthopedic surgery   

general surgery   

neurosurgery   

gynaecological surgery   

abdominal surgery   

mechanical devices for thromboprophylaxis

all type of patients   

orthopaedic surgery   

general non orthopaedic surgery   

pentasaccharide

orthopedic surgery   

abdominal surgery   

medical patients   

all type of patients   

UFH

general surgery   

all type of surgery   

urologic surgery   

cholesterol lowering intervention

all type of patients   

aldosterone blockade

all type of patients   

angiotensin-Converting Enzyme Inhibitors

all type of heart failure   

elderly   

patients with preserved-LVEF heart failure   

MI patients with LV dysfunction without clinical evidence of HF   

angiotensin-receptor blockers

all type of patients   

patients intolerant to ACE inhibitors   

patients previously untreated with ACE inhibitors   

patients already receiving ACE inhibitor   

patients with preserved-LVEF heart failure   

anti inflammatory drugs

all type of patients   

antiarrythmic drugs

all type of heart failure   

antithrombotics

patients hospitalized for heart failure   

all type of patients   

beta-blockers

all type of heart failure   

elderly patients   

BNP guided management

all type of patients   

calcium channel blockers

all type of patients   

cell-based therapies

all types of patients   

cholesterol lowering intervention

elderly   

all type of patients   

combined inhibition of ACE and neprilysin

all type of patients   

digitalis glycosides

all type of patient   

diuretics

patients already taking diuretics   

all type of patients   

Left Ventricular Dysfunction after Myocardial Infarction   

Exercise Therapy

all type of patients   

patients receiving a CRT device   

HR-slowing agents

all type of patients   

increasing hemoglobin concentration

all type of patients   

inhibition of the renin-angiotensin system (ACEI or ARB)

patients with preserved-LVEF heart failure   

Miscellaneous

acute decompensated heart failure   

new drug under development

percutaneous left ventricular assist devices

all type of patients   

phosphodiesterase III inhibitors

all type of patients   

relaxine

acute heart failure   

renin inhibitor

acute decompensated heart failure   

resynchronization (CRT) - defibrillators (ICD)

patients with non ichaemic cardiomyopathy   

all type of patients   

survivors of cardiac arrest   

post myocardial infarction   

mildy symptomatic heart failure with prolonged QRS interval   

surgery

telemonitoring

all type of patients   

vasodilators therapy

all type of patient   

acute decompensated heart failure   

vasopeptidase inhibitor

all type of patients   

vasopressin antagonist

advanced heart failure   

all type of patients   

All mechanism

all type of patients   

angioplasty

all type of patients   

angiotensin-receptor blockers

all diseases requiring ACEi (HF, CHD, HT,...)   

anti hypertensive agent

elderly (60 years and more)   

diabetic patients   

all type of patient   

very ederly (80 and more)   

nephropathy   

post stroke   

patients undergoing dialysis   

patients with treatment-resistant hypertension   

subjects with pre-hypertension   

antiplatelets drug

all type of patients   

cholesterol lowering intervention

all type of patients   

intensive blood pressure control

all type of patients   

diabetic patients   

non diabetic patients   

patients with chronic kidney disease   

renin inhibitor

all type of patients   

diabetic patients   

prevention

all type of patients   

All mechanism

angiotensin-receptor blockers

all type of patients   

All mechanism

all type of patients   

angiotensin-Converting Enzyme Inhibitors

all type of patients   

angiotensin-receptor blockers

all type of patients   

patients intolerant to ACE inhibitors   

inhibition of the renin-angiotensin system (ACEI or ARB)

all type of patients   

catheter ablation

all type of patients   

omega-3 fatty acids

all type of patients   

anti inflammatory drugs

patients undergoing primary angioplasty for AMI   

anti-anginal drugs

hemodialysis patients   

anticoagulant

all type of patients   

patients undergoing primary PCI   

antiplatelets drug

all type of patients   

antithrombotics

all type of patients   

PCI with stent placement   

MI patients undergoing primary PCI   

patients with high residual platelet activity on clopidogrel   

pre treatment for PCI

stable and unstable ACS   

proton-pump inhibitors

patients receiving clopidogrel   

radial access

all type of patients   

restenosis prevention

all type of patients   

statin

all type of patients   

thrombectomy

patients with acute MI   

antioxydants

all type of patients   

diabetic patients   

antiplatelets drug

all type of patient   

antithrombotics

all type of patients   

cell-based therapies

all type of patients   

cholesterol lowering intervention

all type of patients   

Exercise Therapy

all type of patients   

vasodilators therapy

all type of patients   

antioxydants

all type of patients   

antithrombotics

all type of patients   

antiarrythmic drugs

all type of patients   

anticoagulant

all type of patients   

antioxydants

all type of patients   

antiplatelets drug

all type of patient   

antithrombotics

all type of patients   

calcium channel blockers

all type of patients   

cholesterol lowering intervention

all type of patients   

omega-3 fatty acids

all type of patients   

primary prevention of sudden death

secondary prevention

all type of patients   

anti hypertensive agent

all type of patients   

anticoagulant

all type of patients   

antiplatelets drug

all type of patients   

cholesterol lowering intervention

all type of patients   

foramen ovale closure

all type of patients   

prevention

patients with prior stroke or TIA   

prevention

all type of patients   

antiarrythmic drugs

ICD

primary prevention in post MI patients   

resynchronization (CRT) - defibrillators (ICD)

primary prevention   

secondary prevention (survivors of cardiac arrest)   

heart failure   

cholesterol lowering intervention

antithrombotics

all type of patients   

fibrinolysis

all type of patients   

Intravascular Brachytherapy

all type of patients   

new drug under development

anti-anginal drugs

all type of patients   

antibiotics

all type of patient   

antithrombotics

all type of patient   

HR-slowing agents

patients with left ventricular dysfunction   

all type of patients   

myocardial revascularization

all type of patient   

single vessel disease   

multivessels disease   

diabetic patients   

patients with Left Ventricular Dysfunction   

spinal cord stimulation

patients with severe/refractory angina pectoris   

antiplatelets drug

antithrombotics

all type of patients   

dual antiplatelet therapy

all type of patients   

antithrombotics

superficial thrombophlebitis of the leg   

endovascular treatment

all type of patients   

antithrombotics

all type of patients   

patients with cancer   

secondary prevention of VTE   

caval filter

all type of patients   

direct antithrombins

direct factor Xa inhibitors

all type of patients   

direct oral anticoagulant (DAO)

all types of patients   

fibrinolysis

all type of patients   

heparin (UFH or LMWH)

all type of patients   

LMWH

all type of patients   

UFH

all type of patients   

catheter ablation of ventricular tachycardia

all type of patients